Company: IPHYF
Filing Date: 2025-04-30
Form Type: 20-F
Source: 0001598599-25-000042
Chunk: 356

Company: Innate Pharma SA
Filing Date: 2025-04-30
Form: 20-F
Item: Item 19
Chunk 356
---
 in Celiac disease. Takeda would be responsible for the future development, manufacture and commercialization of any potential products developed using the licensed antibodies. As such, the Company considered that the license granted was a right to use the intellectual property, which was granted fully and perpetually to Takeda. The agreement did not stipulate that Innate's activities will significantly affect the intellectual property granted during the life of the agreement. Consequently, the $ 5.0 4.6

On July 25, 2024, the Company received a letter from Takeda terminating the exclusive license agreement signed on March 31, 2023. Termination was effective at the end of a 90

f) Schedule of variance of deferred revenue

The main variance of the global deferred revenue is presented in the following schedule:

  (in thousands of euro)      December 31, 2021                  Recognition in P& L                                                December 31, 2022  
 ───────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
  Monalizumab                                        20,159                               ( 22,376)      47,687      ( 30,989)      14,481             
  Preclinical molecules                              17,400                               ( 17,400)                                 —                  
  Others                                    353                               ( 353)                                                —                  
  Total                                              37,913                               ( 40,129)      47,687      ( 30,989)                         

(1) Of which € 6,560 7,921

  (in thousands of euro)                  Recognition in P& L                 Transfer from collaboration liabilities      December 31, 2023  
 ──────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
  Monalizumab                 14,481                 ( 9,499)                 173                                                      5,155  
  Sanofi options                                     ( 2,500)      5,000      —                                                        2,500  
  Sanofi services                                      ( 374)      3,200      —                                                        2,826  
  Others                                                    —                 —                                                            —  
  Total                       14,481                               8,200      173                                                             

(2) Of which € 5,865 4,618

F-77

  (in thousands of euro)                  Recognition in P& L